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tumorH&E volume that was included in the GTV and positive 
predictive value (PPV), that is the part of the GTV that 
actually was tumor. The distance from each point of the 
common contour to the closest point on the contour of the 
tumorH&E in 3D orientation was measured for tumor 
extensions outside the GTV. This measure quantifies the 
underestimation of the tumor for each observer. 
Results: In a clinical setting (del1) the median GTV (19.6 ml, 
range; 8.0-68.1 ml) is 2.1 times as large as the tumor volume 
(9.2 ml, range: 3.7-42.7 ml). By use of guidelines (GTV del2: 
14.8 ml, range: 5.67-58.32 ml) this factor was decreased to 
1.6. For the first session (del1), 88% (0.88, range: 0.62-0.96) 
of the tumor was included in the GTV (sensitivity). For del2 
the sensitivity decreased to 82% (0.82, range: 0.57-0.96). The 
GTV of del1 consisted for 46% (0.46, range 0.31-0.71) of 
tumor (PPV). For del2 the overestimation decreased and the 
PPV increased to 55% (0.55, range: 0.40-0.79). Adding margin 
of 2.9 mm around the GTV (del1) would cover 95% of the 
tumor extensions currently missed in the GTV. For del2 this 
amounted to 3.8 mm.  
Conclusions: In a clinical setting the GTV overestimates the 
actual tumor volume as determined by histopathology and 
which improved considerably by the implementation of 
guidelines (figure). These guidelines decreased the sensitivity 
slightly. This might be explained by registration uncertainties 
which appear more prominent when the accuracy of the 
delineation increases.  
1 Becker M et al. Neoplastic invasion of laryngeal cartilage: 
reassessment of criteria for diagnosis at MR imaging. 
Radiology. 2008 Nov;249(2):551-9.  
 
 
   
 
PD-0420   
Randomised escalation trial with adaptive dose painting by 
numbers for head and neck cancer: interim analysis 
F. Duprez1, D. Berwouts1, T. Boterberg1, W. De Gersem1, L. 
Olteanu1, T. Vercauteren1, W. De Neve1 
1Ghent University Hospital, Radiotherapy, Gent, Belgium  
 
Purpose/Objective: Late mucosal ulcers appeared to be 
dose-limiting toxicity (DLT) in a previous phase-I-escalation 
trial for head and neck squamous cell carcinoma (HNC) using 
18F-FDG-PET-CT guided dose-painting-by-numbers (DPBN). A 
prospective randomised phase II trial is currently 
investigating whether 3-phase adaptive DPBN using the 
maximally tolerated dose will result in better locoregional 
control compared to standard IMRT (S-IMRT). This interim 
analysis reports on local (LC), regional (RC), distant control 
(DC), overall survival (OS) and xerostomia, dysphagia and 
mucosal integrity at ≥ 3 months.  
Materials and Methods: From 2011, Q3 to 2014, Q3 34 
patients received primary radio(chemo)therapy for HNC. We 
report on 28 patients who have ended therapy for ≥ 3 
months. Patient, tumor and treatment characteristics can be 
found in Table 1. 
 
 
Figure 1 demonstrates dose prescription protocols (DPP) of 
the DPBN- and S-IMRT group.  
 
 
Results: Median follow-up in living patients was 13 (3-34) 
months. Eight patients deceased: 5 DPBN-patients (due to 
metastases (n = 3), complications after neck dissection for 
regional recurrence (n = 1) and unknown cause (n = 1)) and 3 
S-IMRT patients (due to metastases (n = 2) and aspiration 
pneumonia (n = 1)). 
Local recurrence was seen in n = 2 (14%) in the S-IMRT-group. 
One regional recurrence in elective neck was seen in the 
DPBN-group. Metastases were seen in 5 and 3 patients in the 
DPBN- and S-IMRT-group, respectively. One patient 
interrupted DPBN due to distant metastases after fraction 28 
and deceased 1 month later which made local evaluation at 3 
months impossible. 
At 1 year actuarial LC was 100% and 80% (p = 0.13), RC 90% 
and 100% (p = 0.8), DC 76% and 90% (p = 0.7) and OS 59% and 
92% (p = 0.48) in DPBN and S-IMRT, respectively.  
We unexpectedly observed grade (G)3 and 4 mucosal ulcers in 
1/7 and 3/7 DPBN-patients in DPP1 for which laryngectomy 
and partial mandibulectomy were needed (n = 2) for 
associated chondro- and osteoradionecrosis. In order to avoid 
G4 mucosal LT the DPBN-DPP has been adapted in 2 steps 
(Fig. 1): DPP1 used a median dose prescription that can result 
in increased doses in a GTV with > 50% voxels of low-uptake. 
This median dose prescription was abandoned in DPP2. In 
DPP3 the very-high dose region has been limited to an 
absolute volume of 1.75 cc.  
In DPP2 and DPP3, 1/2 and 1/5 patients had G3 mucosal LT, 
respectively, that healed spontaneously in the patient from 
DPP2 and could't be followed up in the DPP3-patient as he 
deceased due to distant metastases.  
Late G3 dysphagia was seen in 1 and 2 DPBN and S-IMRT 
patients at month 3, respectively. Maximal dysphagia grade 
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was 2 at ≥ 6 months follow-up. 1 DPBN-patient had G3 
xerostomia at month 3 that reduced to G1 thereafter. 
Conclusions; There were no local recurrences in the DPBN-
group. We did not observe significant differences in LC, RC, 
DC or OS until now. Due to mucosal LT, the DPBN-DPP has 
been adapted. Since then, no G4 mucosal LT was observed. 
Another 66 patients will be recruited for the study.  
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Purpose/Objective: Concurrent cisplatin and radiation (cisp-
RT) can achieve high locoregional control and survival for 
locally advanced head and neck cancer (LAHNC) particularly 
in the oropharynx, HPV+, and non-smokers. Recent 
retrospective reviews challenge the role of cetuximab plus 
radiation in this population suggesting inferior outcomes, 
which needs to be further confirmed. HPV negative head and 
neck cancer patients seem to do far worse with current 
strategies. This study compares concurrent cisp-RT with 
radiation plus anti-EGFR moAb (anti-EGFR-RT) in LAHNC in a 
population that is mainly HPV negative. The prognostic value 
of HER3 pathway-related biomarkers is explored. 
Materials and Methods: From 1999 to 2010, 108 LAHNC 
patients with oral cavity, oropharynx, hypopharynx or larynx 
tumors received definitive treatment with cisp-RT (n= 71) or 
anti-EGFR-RT (n=37). Of these, 86 patients had tissue 
available for HPV analysis (PCR and p16), and 48 for HER3 
pathway analysis. Outcomes were analyzed by the Kaplan-
Meier method, Cox model and competing-risks analysis tools. 
Results: 88% of the analyzed samples were HPV negative. 
Patient characteristics include 77% smokers, 70% heavy 
alcohol intake, 49% T4 and 69% N2-3. The anti-EGFR-RT 
patients were older. At a median follow-up of 4.2 years, the 
2- and 5-year locoregional failure rates were 34.1% and 41.8% 
for cisp-RT vs 60.1% and 71.5% for anti-EGFR-RT (p=0.015). 
These differences remained significant for progression-free 
survival (p=0.0006) and were lost when distant metastasis 
was the only site of relapse (p=0.24). Metastasis-only relapse 
occurred in 14.8% of patients. In multivariate analysis, cisp-
RT predicted for locoregional relapse (HR=0.53, 95%CI: 0.31-
0.92, p=0.024) and progression-free survival (HR=0.44, 95%CI: 
0.27-0.71, p=0.0009), whereas hypopharynx/larynx primaries 
(HR=5.13, 95%CI: 1.50-17.51, p=0.013) and T4 tumors 
(HR=2.95, 95%CI: 1.05-8.31, p=0.041) predicted for 
metastasis-only relapse. Subgroup analysis of HER3 pathway-
related biomarkers adjusted for significant risk variables 
identified overexpression of pS6 (p=0.009) and p53 (p=0.049) 
as prognostic for locoregional failure, and pS6 (p=0.016) and 
HER3 (p=0.049) expression for metastasis-only relapse.  
Conclusions: Superior outcomes with concurrent cisp-RT in 
LAHN patients are observed in a predominantly HPV negative 
population. It is of clinical relevance that 
hypopharynx/larynx primaries and T4 tumors predicted for 
metastasis as the only site of relapse in such a high risk 
group. Exploratory analyses suggest that pS6 and p53 
expression predict for locoregional failure and that pS6 and 
HER3 do for metastasis-only relapse. 
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Purpose/Objective: Data quality of routine patients is of 
vital importance when creating an infrastructure for rapid 
learning. The aim of this work is to provide a platform that 
enables rapid learning for laryngeal carcinoma patients and 
prove the clinical relevance of a survival prediction model as 
a first step to multi institutional rapid learning. In this study 
we present a first rapid learning approach that combines 
learning a decision support system from MAASTRO Clinic 
('training cohort') and validating it in both the Illawarra 
Cancer Care Centre ('clinical cohort') and the RTOG-91-11 
clinical trial dataset ('trial cohort'). 
Materials and Methods: Data extraction and mining tools 
were used to collect the input parameters from the clinical 
cohort's OIS system (MosaiQ). The training cohort was used to 
determine the prognosis range for good, medium and poor 
prognosis patients so it could be applied to the clinical cohort 
and to validate the new implementation of the model. To 
evaluate the model performance the Area Under the Curve 
(AUC) spread for each dataset was calculated using 
bootstrapping. A similar approach was applied to the 
radiotherapy only arm of the trial cohort. The resulting 
Kaplan-Meier survival curves for the good, medium and poor 
prognosis groups are displayed for each separate cohort. 
Results: Data mining identified 125 laryngeal carcinoma 
patients, resulting in 109 that were eligible to be evaluated 
by the model to predict 2 year survival. Bootstrapping 
resulted in a normally distributed AUC reliability interval 
(95% CI) of 0.61 to 0.84, 0.47 to 0.67 and 0.74 to 0.82 for the 
clinical, trial and training cohorts respectively. The predicted 
prognostic survival groups resulted in the Kaplan Meier curves 
presented in Figure 1. The survival prediction thresholds to 
create the poor, medium and good prognosis groups were 57% 
and 81% chance of 2 year survival. This resulted in a group 
distribution of 47%, 42% and 11% and 53%, 42% and 5% for the 
